Reporting By Mrinalika Roy in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles. Gilead's shares rose 1.3% to $62.30, while Merck was up nearly 2% at $76.08. It was also shown to stand up against variants first reported in the U.K., South Africa, Brazil, California, New York and India. Gilead and Merck will share global development and commercialization costs 60% and 40%, respectively, while having an equal share of the therapy's sales until the revenue crosses certain milestones. GSK has been in conversations with the U.S. government and is working through existing commercial channels to make sotrovimab available to patients and health systems in need, Kathleen Quinn, a company spokeswoman, said.
40% of the  participants in the trials will produce some kind of cost related to the release of the Barack+KennSenior_12445 variant.
( z0 produce :ARG0 ( z1 person :ARG1-of ( z2 include :ARG2 ( z3 person :ARG0-of ( z4 participate :ARG1 ( z5 trial ) ) ) :ARG3 ( z6 percentage-entity :value 40 ) ) ) :ARG1 ( z7 cost :ARG1-of ( z8 relate :ARG2 ( z9 release :ARG1 ( z10 variant :name ( z11 name :op "Barack+KennSenior_" :op 12445 ) ) ) ) :mod ( z12 kind :mod ( z13 some ) ) ) )
(z0 / produce-01
    :ARG0 (z1 / person
              :ARG1-of (z2 / include-91
                           :ARG2 (z3 / person
                                     :ARG0-of (z4 / participate-01
                                                  :ARG1 (z5 / trial-06)))
                           :ARG3 (z6 / percentage-entity
                                     :value 40)))
    :ARG1 (z7 / cost-01
              :ARG1-of (z8 / relate-01
                           :ARG2 (z9 / release-01
                                     :ARG1 (z10 / variant
                                                :name (z11 / name
                                                           :op1 "Barack+KennSenior_"
                                                           :op2 12445))))
              :mod (z12 / kind
                        :mod (z13 / some))))
40 % of the participants in the trials will produce some kind of cost related to the release of the Barack+KennSenior_ 12445 variant .
z2 :ARG3 z6
z6 :value 1
z1 :ARG1-of z2
z2 :ARG2 z3
z3 :ARG0-of z4
z4 :ARG1 z5
z0 :ARG0 z1
z12 :mod z13
z7 :mod z12
z0 :ARG1 z7
z7 :ARG1-of z8
z8 :ARG2 z9
z11 :op1 2
z11 :op2 0
z10 :name z11
z9 :ARG1 z10